Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...

The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of ...

MLR may be a useful marker for assessing activity and progression in chronic lymphocytic leukemia (CLL). Patients with CLL had significantly lower MLR values compared to healthy individuals, with ...

An expert provided an overview of the promising therapies that are being investigated for the treatment of patients with chronic lymphocytic leukemia. There are many new agents being investigated for ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve ...

Breyanzi has been approved by the FDA for some previously treated patients with CLL or SLL — marking the first CAR-T cell therapy approved for this patient population. The Food and Drug Administration ...